What is MedRhythms?
Founded in 2015, MedRhythms is at the forefront of neurorehabilitation, utilizing Neurologic Music Therapy (NMT) to facilitate recovery for individuals impacted by brain injuries and neurological diseases. The company collaborates with prominent rehabilitation hospitals across the United States, offering comprehensive services that span outpatient, in-home, community, and telehealth settings. MedRhythms' interventions are meticulously designed to achieve optimal outcomes in sensorimotor, speech and language, and cognitive functions for diverse patient populations, including those recovering from traumatic brain injury, stroke, and neurodegenerative conditions. Their commitment to clinical excellence and continuous innovation positions them as a key player in advancing NMT and enhancing the quality of life for patients across various care levels.
How much funding has MedRhythms raised?
MedRhythms has raised a total of $5.7M across 3 funding rounds:
Series A
$5.3M
Debt
$150K
Debt
$272K
Series A (2018): $5.3M, investors not publicly disclosed
Debt (2020): $150K led by PPP
Debt (2021): $272K supported by PPP
Key Investors in MedRhythms
PPP
Public-Private Partnership
PPP
Public-Private Partnership
What's next for MedRhythms?
The substantial enterprise-level capital infusion signifies MedRhythms' readiness for significant scaling and market expansion. This strategic backing is expected to accelerate the development and deployment of their NMT solutions, potentially broadening their reach to new patient demographics and geographical markets. Further investment will likely focus on enhancing their technological platform, expanding clinical partnerships, and deepening their research into the efficacy of music-based therapies. MedRhythms is poised to solidify its leadership in the neurorehabilitation sector, driving innovation and improving patient outcomes through its unique therapeutic approach.
See full MedRhythms company page
